Showing 3861-3870 of 4063 results for "".
- NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFOhttps://modernod.com/news/novabay-pharmaceuticals-appoints-justin-hall-president-and-ceo-and-jason-raleigh-cfo/2476666/NovaBay Pharmaceuticals announced the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Mr. Hall has served as interim President and CEO, and Mr. Raleigh as interim CFO since March 2019. “Justin and Jason have proven their l
- Research Shows Gene Therapy May Restore Visual Function for People With Night Blindnesshttps://modernod.com/news/research-shows-gene-therapy-may-restore-visual-function-for-people-with-night-blindness/2476663/By isolating where a key protein required for low light vision is expressed, scientists have shown that gene therapy may restore visual function for people with a form of congenital stationary night blindness. In mice models with genetic mutations similar to humans with night blindness, sc
- Glaucoma Drugs Continue to Battle for Market Sharehttps://modernod.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/Two new glaucoma drugs introduced in the US in 2018 continue to battle for market share. Rhopressa, from Aerie Pharmaceuticals, got out of the gate faster than Vyzulta from Bausch Health. The growth rate for both drugs slowed in the first quarter of 2019, which is normal after a product launch, a
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b
- More Elderly Americans Dying From Fallshttps://modernod.com/news/more-elderly-americans-dying-from-falls/2476634/Death rates from falls are rising among elderly Americans and climbing fastest among seniors in their 90s, a US study suggests. Among all adults 75 and older, mortality from falls climbed 5.1% from 2000 to 2016, researchers report in JAMA. Death rates from falls rose the most—6.4%—among
- Medical Specialty Organizations Applaud Introduction of Congressional Legislation to Improve Transparency in Prior Authorizationhttps://modernod.com/news/medical-specialty-organizations-applaud-introduction-of-congressional-legislation-to-improve-oversight-and-transparency-in-prior-authorization/2476633/A coalition of eight national medical specialties, including the American Academy of Ophthalmology, pledged support for the bipartisan “Improving Seniors’ Timely Access to Care Act of 2019” (H.R. 3107) legislation that aims to protect patients from unreasonable Medicare Advantag
- New Biomarker Research Builds Furthers Understanding of Tebentafusp Mechanism of Action in Advanced Melanomahttps://modernod.com/news/new-biomarker-research-builds-furthers-understanding-of-tebentafusp-mechanism-of-action-in-advanced-melanoma/2476624/Monotherapy treatment with the first-in-class ImmTAC molecule tebentafusp (IMCgp100) induced an immunologically potent response in patients with advanced uveal and cutaneous melanoma, according to new data presented today by Immunocore Limited at the 2019 American Society of Clinical Oncology (AS
- Study: 3D Printed Artificial Corneas Similar to Human Oneshttps://modernod.com/news/study-3d-printed-artificial-corneas-similar-to-human-ones/2476615/When a person has a severely damaged cornea, a corneal transplant is required. However, there are 2,000 patients waiting for the cornea donation in the country as of 2018, and they wait for 6 or more years on average for the donation. For this reason, many scientists have put their efforts in dev
- Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for Dextenza (dexamethasone ophthalmic insert). The code, C9048, is scheduled to become effective July 1, 2019.
- Zeiss Ranked Best Company in Germany’s Public Value Atlashttps://modernod.com/news/zeiss-ranked-best-company-in-germanys-public-value-atlas/2476600/Zeiss is Germany’s highest-ranked company in the 2019 Public Value Atlas (Gemeinwohlatlas 2019). The announcement was made in Berlin by the authors of the study, the Center for Leadership and Values in Society at the University of St. Gallen (CLVS-HSG) in cooperation with the Dr. Arend Oetk